This study looks at how a lack of oxygen, called *hypoxia*, affects treatment in people with liver cancer that has spread to a few places. The treatment, known as Yttrium-90 (Y90) selective internal radiation therapy, uses tiny radioactive beads to target the cancer directly. This method helps stop blood from reaching the tumor while delivering high radiation to kill cancer cells without damaging healthy tissue. The study uses special imaging tests, BOLD MRI and FMISO PET, to measure how much oxygen is in the tumor before treatment. These tests help predict how well the cancer will respond to the therapy. Patients in the study will receive a special injection and have imaging tests within 30 days before starting the Y90 treatment. Follow-ups are done 90 days after and every 12 weeks. Participation is open to adults with a specific type of liver cancer, known as hepatocellular carcinoma (HCC), who meet the study's eligibility criteria.

• The study involves imaging tests and standard Y90 treatment.
• Follow-up visits are scheduled every 12 weeks after initial 90 days.
• Participants must use contraception and meet specific health criteria.